The state of New York currently has 13 active clinical trials seeking participants for Pulmonary Fibrosis research studies. These trials are conducted in various cities, including New York, Rochester, Bronx and Buffalo.
Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
Recruiting
The primary purpose of this multi-center, double-blind, placebo-controlled, dose-ranging Phase I study is to assess the safety of a purified from green tea, EGCG, in patients with idiopathic pulmonary fibrosis (IPF) as a potential novel treatment for pulmonary fibrosis.
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
10/15/2024
Locations: Weill Cornell Medicine, New York, New York
Conditions: Idiopathic Pulmonary Fibrosis